Art. -Nr.: HY-124584

Minnelide

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Minnelide is a prodrug of triptolide that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide promotes apoptosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.91%
CAS. Nr.: 1254702-87-8
Formel: C₂₁H₂₅Na₂O₁₀P
Molecular Weight:514.37

Speicherung:

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Minnelide Chemical Structure

CAS. Nr.: 1254702-87-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Minnelide is a prodrug of triptolide that shows potent antitumor activity in a number of tumor types, particularly in pancreatic cancer. Minnelide promotes apoptosis^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
PANC-1	IC₅₀	0.2 μM Compound: 8h	Cytotoxicity against human Panc-1 cells incubated for 48 hrs by CCK8 assay Cytotoxicity against human Panc-1 cells incubated for 48 hrs by CCK8 assay	[PMID: 33289552]

In Vitro

Minnelide (0-200 nM; 48 hours) shows significantly decreased cell viability in pancreatic cancer cell lines after treatment in the presence, but not in the absence, of phosphatase^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

Pancreatic cancer cell line: S2-013, MIA PaCa-2, S2-VP10, and Panc-1 cells
Concentration:

0.100 nM, 200 nM
Incubation Time:

48 hours
Result:

Decreased cell viability of in vitro.

In Vivo

Minnelide (injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily) leads to a marked decrease in tumor weight and volume at the end of treatment and increases survival in orthotopic model of pancreatic cancer with MIA PaCa-2–derived human pancreatic tumors^[2].
Minnelide (injection intraperitoneally; 0.42 mg/kg; once daily; 28 days) prevents locoregional spread and leads to a decrease in average tumor weight in a xenograft model of pancreatic cancer with metastatic S2-013 cells^[2].
Minnelide (injection intraperitoneally; 0.42 mg/kg, 0.21 mg/kg; once daily) causes tumor regression and tumors from Minnelide-treated animals showed fibrosis and the presence of pyknotic nuclei in human pancreatic cancer xenografts in SCID mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Orthotopic model of pancreatic cancer with MIA PaCa 2-derived human pancreatic tumors in athymic nude mice^[2]
Dosage:

0.1-0.6 mg/kg
Administration:

Injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily
Result:

Prevented pancreatic tumor growth in vivo.

Animal Model:

Xenograft model of pancreatic cancer with metastatic S2-013 cell line in athymic nude mice^[2]
Dosage:

0.42 mg/kg
Administration:

Injection intraperitoneally; 0.42 mg/kg; once daily
Result:

Prevented extensive spread from the primary site of injection.

Animal Model:

Human pancreatic cancer xenografts in SCID mice^[2]
Dosage:

0.21 mg/kg, 0.42 mg/kg
Administration:

Injection intraperitoneally; 0.42 mg/kg; once daily
Result:

Reduced tumor burden in human xenografts from patients.

Chemical Information

CAS. Nr. 1254702-87-8
Appearance Solid
Molecular Weight 514.37
Formel C₂₁H₂₅Na₂O₁₀P
Color White to off-white
SMILES

C[C@@]12[C@@]34[C@]([C@@H]5C[C@@]1([H])C6=C(C(OC6)=O)CC2)(O5)[C@@H]([C@](O7)(C(C)C)[C@@H]7[C@@H]3O4)OCOP(O[Na])(O[Na])=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Publications (3)

All Cell Proliferation/Viability AssayApoptosis AnalysisWBIn Vivo Efficacy StudyIn Vivo Imaging

Sort by:

Journal Impact Factor

J Clin Invest

Targeting CIC::DUX4 sarcoma with Minnelide in a dual recombinase-initiated genetically engineered mouse model. [Abstract]

2026 Jun 16:e202218. PMID: 42302177
Phytomedicine

Minnelide exhibits antileukemic activity by targeting the Ars2/miR-190a-3p axis. [Abstract]

2024 May 11:130:155724. PMID: 38759317
Res Sq

Dual activity of Minnelide chemosensitize basal/triple negative breast cancer stem cells and reprograms immunosuppressive tumor microenvironment. [Abstract]

2024 Feb 22:rs.3.rs-3959342. PMID: 38464167

Minnelide purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]

Human breast cancer cell lines, MDA-MB231, Sum159, ZR75–1, MCF7 AND murine breast cancer cell lines, EMT6, E00771, AT3 and 4T1 were incubated with indicated doses of Minnelide (0, 25, 50, 75, 100 μM) for 48 hours and cell viability was measured by MTT assay.

Minnelide purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]

Breast cancer cell lines, MDA-MB-231 and MCF7 were incubated with indicated doses of Minnelide (0, 25, 50, 75 μM) for 48 hours and apoptotic cell death and CSC population was evaluated by flow cytometer.

Minnelide purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]

Protein expression of HSP70/72, A20, Vimentin, MYC and BRD4 was shown in human MDA-MB-231 and murine 4T1 and EMT6 cell lines treated with increased dose of Minnelide in the presence and absence of recombinant human TGFβ.

Minnelide purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]

Size of primary tumors and their weights at the end point of the experiment treated with single Minnelide (0.5 mg/kg).

Minnelide purchased from MedChemExpress. Usage Cited in: Res Sq. 2024 Feb 22:rs.3.rs-3959342. [Abstract]

Minnelide (0.5 mg/kg) alone significantly reduced the relapse after surgery, and it eliminated all residual tumors when combined with CTX. D. Survival rates of 4T1 tumor bearing mice before and after the resections.

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 100 mg/mL (194.41 mM; Need ultrasonic)

DMSO : 16.67 mg/mL (32.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9441 mL

9.7206 mL

19.4413 mL

5 mM

0.3888 mL

1.9441 mL

3.8883 mL

10 mM

0.1944 mL

0.9721 mL

1.9441 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.67 mg/mL (3.25 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.67 mg/mL (3.25 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.67 mg/mL (3.25 mM); Clear solution

This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (288 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Noel P, et al. Triptolide and Its Derivatives as Cancer Therapies. Trends Pharmacol Sci. 2019 May;40(5):327-341. [Content Brief]

[2]. Chugh R, et al. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med. 2012 Oct 17;4(156):156ra139. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	1.9441 mL	9.7206 mL	19.4413 mL	48.6031 mL
	5 mM	0.3888 mL	1.9441 mL	3.8883 mL	9.7206 mL
	10 mM	0.1944 mL	0.9721 mL	1.9441 mL	4.8603 mL
	15 mM	0.1296 mL	0.6480 mL	1.2961 mL	3.2402 mL
	20 mM	0.0972 mL	0.4860 mL	0.9721 mL	2.4302 mL
	25 mM	0.0778 mL	0.3888 mL	0.7777 mL	1.9441 mL
	30 mM	0.0648 mL	0.3240 mL	0.6480 mL	1.6201 mL
H₂O	40 mM	0.0486 mL	0.2430 mL	0.4860 mL	1.2151 mL
	50 mM	0.0389 mL	0.1944 mL	0.3888 mL	0.9721 mL
	60 mM	0.0324 mL	0.1620 mL	0.3240 mL	0.8101 mL
	80 mM	0.0243 mL	0.1215 mL	0.2430 mL	0.6075 mL
	100 mM	0.0194 mL	0.0972 mL	0.1944 mL	0.4860 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Minnelide

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Minnelide

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Minnelide

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Minnelide

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Minnelide

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Minnelide Related Classifications

HY-124584 Related Classifications